Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| MERCURY SYSTEMS INCMRCY · Entity 3908 | Director | May 26, 2026 | May 27, 2026 |
| Maxar Technologies Inc.MAXR · Entity 113823 | Director · President and CEO | January 01, 2019 | January 10, 2019 |
| New Vista Acquisition CorpNVSA · Entity 142588 | Director | February 16, 2021 | February 17, 2021 |
| STRYKER CORPSYK · Entity 369 | Director | March 21, 2014 | March 21, 2014 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
MERCURY SYSTEMS INC
Report date May 26, 2026 · Filed May 27, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBy The Howard L. Lance Revocable Living Trust Dated 9/1/2006 | 1,250 |
Reported balance
After 2026-05-26 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2026-05-26 · Sale · Disposed 8,000 · Balance 1,250 F1: This transaction was executed in multiple trades at prices ranging from $99.3600 to $100.4501. The price reported above reflects the weighted average purchase price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. |
| Common StockSEC Table I · non-derivative | IndirectBy The Howard L. Lance Revocable Living Trust Dated 9/1/2006 | 0 |
Reported balance
After 2026-05-26 transaction · row 2
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 2 · 2026-05-26 · Sale · Disposed 1,250 · Balance 0 F2: This transaction was executed in multiple trades at prices ranging from $98.1000 to $98.9000. The price reported above reflects the weighted average purchase price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. |
| Common StockSEC Table I · non-derivative | Direct | 27,272 |
Reported balance
Holding disclosure · report date 2026-05-26 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 27,272 |
Filing footnotes · ownership attribution and instrument terms
F1: This transaction was executed in multiple trades at prices ranging from $99.3600 to $100.4501. The price reported above reflects the weighted average purchase price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F2: This transaction was executed in multiple trades at prices ranging from $98.1000 to $98.9000. The price reported above reflects the weighted average purchase price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
Maxar Technologies Inc.
Report date January 01, 2019 · Filed January 10, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 176,221 |
Reported balance
Holding disclosure · report date 2019-01-01 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 176,221 F1: Amount reported includes 44,323 unvested Restricted Stock Units ("RSUs"), which were granted on December 14, 2017 and vest as follows: 22,161 shares vest on December 14, 2019 and 22,162 December 14, 2020. |
| Stock Appreciation Right - 2016 PlanSEC Table II · derivative / convertible security · Conversion / exercise price $69.78 · Expires 2021-05-01 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2019-01-01 · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · Balance Not disclosed F2: Long Term Incentive Plan ("LTIP") Units awarded under the 2016 LTIP Plan ("2016 LTIP Plan") vest in thirds on the first, second, and third anniversaries of the date of grant. The maturity date of LTIP unit awards under the 2016 LTIP Plan is midnight on the fifth anniversary of the date of grant. |
| Stock Appreciation Right - 2017 PlanSEC Table II · derivative / convertible security · Conversion / exercise price $49.79 · Expires 2026-11-30 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2019-01-01 · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · Balance Not disclosed F3: LTIP Units awarded under the 2017 LTIP Plan vest in quarters on the first, second, third and fourth anniversaries of the date of grant. The maturity date of LTIP awards under the 2017 LTIP Plan is midnight on the tenth anniversary of the date of grant. |
| 2018 LTIP - Omnibus PlanSEC Table II · derivative / convertible security · Conversion / exercise price $66.03 · Expires 2027-12-31 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2019-01-01 · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · Balance Not disclosed F4: LTIP Units awarded under the Omnibus Equity Incentive Plan ("Omnibus Plan") vest in four equal annual installments beginning on the first anniversary of the date of grant. The maturity date of LTIP awards under the Omnibus Plan is midnight on the tenth anniversary of the date of grant. |
Filing footnotes · ownership attribution and instrument terms
F1: Amount reported includes 44,323 unvested Restricted Stock Units ("RSUs"), which were granted on December 14, 2017 and vest as follows: 22,161 shares vest on December 14, 2019 and 22,162 December 14, 2020.
F2: Long Term Incentive Plan ("LTIP") Units awarded under the 2016 LTIP Plan ("2016 LTIP Plan") vest in thirds on the first, second, and third anniversaries of the date of grant. The maturity date of LTIP unit awards under the 2016 LTIP Plan is midnight on the fifth anniversary of the date of grant.
F3: LTIP Units awarded under the 2017 LTIP Plan vest in quarters on the first, second, third and fourth anniversaries of the date of grant. The maturity date of LTIP awards under the 2017 LTIP Plan is midnight on the tenth anniversary of the date of grant.
F4: LTIP Units awarded under the Omnibus Equity Incentive Plan ("Omnibus Plan") vest in four equal annual installments beginning on the first anniversary of the date of grant. The maturity date of LTIP awards under the Omnibus Plan is midnight on the tenth anniversary of the date of grant.
New Vista Acquisition Corp
Report date February 16, 2021 · Filed February 17, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class B ordinary sharesSEC Table II · derivative / convertible security | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2021-02-16 · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · Balance Not disclosed F1: As described in the issuer's registration statement on Form S-1 (File No. 333-252622) under the heading "Description of Securities--Founder Shares," the Class B ordinary shares of the issuer, par value $0.0001 per share, will automatically convert into Class A ordinary shares of the issuer, par value $0.0001 per share, at the time of the issuer's initial business combination, or earlier at the option of the holder, on a one-for-one basis, subject to certain adjustments, and have no expiration date. |
Filing footnotes · ownership attribution and instrument terms
F1: As described in the issuer's registration statement on Form S-1 (File No. 333-252622) under the heading "Description of Securities--Founder Shares," the Class B ordinary shares of the issuer, par value $0.0001 per share, will automatically convert into Class A ordinary shares of the issuer, par value $0.0001 per share, at the time of the issuer's initial business combination, or earlier at the option of the holder, on a one-for-one basis, subject to certain adjustments, and have no expiration date.
STRYKER CORP
Report date March 21, 2014 · Filed March 21, 2014
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 18,519 |
Reported balance
After 2014-03-21 transaction · row 1
1 source rowRow 1 · 2014-03-21 · Exercise / conversion · Acquired 1,380 · Balance 18,519 F1: On March 21, 2014, 1,380 Restricted Stock Units vested and were settled for an equal number of shares of Stryker Common Stock. |
| Common StockSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2014-03-21 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2014-03-21 · Exercise / conversion · Disposed 1,380 · Balance 0 F1: On March 21, 2014, 1,380 Restricted Stock Units vested and were settled for an equal number of shares of Stryker Common Stock. |
Filing footnotes · ownership attribution and instrument terms
F1: On March 21, 2014, 1,380 Restricted Stock Units vested and were settled for an equal number of shares of Stryker Common Stock.
Past disclosures · reporting ended (2)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Change Healthcare Inc.
Report date October 03, 2022 · Filed October 05, 2022
Section 16 reporting ended · disclosed 2022-10-05. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Ending reported balance
After 2022-10-03 transaction · row 3
3 source rows · reconciled sequenceRow 1 · 2022-10-03 · Disposition to issuer · Disposed 211,720 · Balance 14,794 F1: On October 3, 2022, UnitedHealth Group Incorporated ("UnitedHealth Group") acquired Change Healthcare Inc. (the "Issuer") pursuant to that certain Agreement and Plan of Merger dated as of January 5, 2021 (the "Merger Agreement") by and among the Issuer, UnitedHealth Group and Cambridge Merger Sub Inc., a wholly owned subsidiary of UnitedHealth Group ("Merger Sub"). In accordance with the Merger Agreement, Merger Sub merged with and into the Issuer (the "Merger"), with the Issuer surviving the Merger as a wholly owned subsidiary of UnitedHealth Group. At the effective time of the Merger (the "Effective Time"), each issued and outstanding share of common stock, par value $0.001 per share, of the Issuer (the "Common Stock") (other than certain excluded shares) automatically converted into the right to receive $25.75 per share in cash (the "Merger Consideration"), without interest and less any applicable holding tax. Row 2 · 2022-10-03 · Disposition to issuer · Disposed 7,136 · Balance 7,658 F2: At the Effective Time of the Merger, all deferred stock units of the Issuer automatically vested and were automatically converted into UnitedHealth Group deferred stock units calculated by taking the merger consideration of $25.75 per share of Common Stock and dividing it by the volume weighted average of the closing sale prices per share of UnitedHealth Group common stock on each of the five full consecutive trading days ending on and including the third business day prior to the Merger closing date (the "Equity Award Exchange Ratio") and continue to be subject to the same terms and conditions (including settlement terms) as were applicable to the Issuer deferred stock units. Row 3 · 2022-10-03 · Disposition to issuer · Disposed 7,658 · Balance 0 F3: At the Effective Time of the Merger, all restricted stock units of the Issuer automatically vested and were automatically converted into United restricted stock units calculated by taking the merger consideration of $25.75 per share of Common Stock of the Issuer and dividing it by the Equity Award Exchange Ratio and continue to be subject to the same terms and conditions (including settlement terms) as were applicable to the Issuer restricted stock units. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $18.99 · Expires 2027-10-17 | Direct | 0 |
Reported balance
After 2022-10-03 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2022-10-03 · Disposition to issuer · Disposed 40,448 · Balance 0 F5: In connection with the Merger, stock option awards of the Issuer were automatically converted into an option to purchase a number of shares of common stock of UnitedHealth Group equal to the product of (i) the number of shares of Common Stock subject to the Issuer stock option multiplied by (ii) the Equity Award Exchange Ratio, at an exercise price per share equal to (i) the exercise price of the Issuer stock option divided by (ii) the Equity Award Exchange Ratio. Except as described herein, the UnitedHealth Group options will continue to be subject to the same terms and conditions as were applicable to the existing Issuer stock option. F4: These options are fully vested. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $18.99 · Expires 2028-05-25 | Direct | 0 |
Reported balance
After 2022-10-03 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2022-10-03 · Disposition to issuer · Disposed 6,320 · Balance 0 F5: In connection with the Merger, stock option awards of the Issuer were automatically converted into an option to purchase a number of shares of common stock of UnitedHealth Group equal to the product of (i) the number of shares of Common Stock subject to the Issuer stock option multiplied by (ii) the Equity Award Exchange Ratio, at an exercise price per share equal to (i) the exercise price of the Issuer stock option divided by (ii) the Equity Award Exchange Ratio. Except as described herein, the UnitedHealth Group options will continue to be subject to the same terms and conditions as were applicable to the existing Issuer stock option. F4: These options are fully vested. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.92 · Expires 2022-11-28 | Direct | 0 |
Reported balance
After 2022-10-03 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2022-10-03 · Disposition to issuer · Disposed 28,828 · Balance 0 F5: In connection with the Merger, stock option awards of the Issuer were automatically converted into an option to purchase a number of shares of common stock of UnitedHealth Group equal to the product of (i) the number of shares of Common Stock subject to the Issuer stock option multiplied by (ii) the Equity Award Exchange Ratio, at an exercise price per share equal to (i) the exercise price of the Issuer stock option divided by (ii) the Equity Award Exchange Ratio. Except as described herein, the UnitedHealth Group options will continue to be subject to the same terms and conditions as were applicable to the existing Issuer stock option. F4: These options are fully vested. |
| Stock Appreciation rightSEC Table II · derivative / convertible security · Conversion / exercise price $0.38 · Expires 2023-05-22 | Direct | 0 |
Reported balance
After 2022-10-03 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2022-10-03 · Disposition to issuer · Disposed 45,758 · Balance 0 F6: These stock appreciation rights ("SARs") are fully vested. Pursuant to the Merger Agreement, the SARs were automatically converted into SARs of UnitedHealth Group, denominated in a number of shares of common stock of UnitedHealth Group equal to the product of the number of shares of Common Stock subject to the Issuer SARs multiplied by the Equity Award Exchange Ratio, at an exercise price per share equal to the strike price per share applicable to such SAR divided by the Equity Award Exchange Ratio. The UnitedHealth Group SARs will continue to be subject to the same terms and conditions as were applicable to the Issuer SARs. |
| Stock Appreciation rightSEC Table II · derivative / convertible security · Conversion / exercise price $0.38 · Expires 2022-11-28 | Direct | 0 |
Reported balance
After 2022-10-03 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2022-10-03 · Disposition to issuer · Disposed 11,439 · Balance 0 F6: These stock appreciation rights ("SARs") are fully vested. Pursuant to the Merger Agreement, the SARs were automatically converted into SARs of UnitedHealth Group, denominated in a number of shares of common stock of UnitedHealth Group equal to the product of the number of shares of Common Stock subject to the Issuer SARs multiplied by the Equity Award Exchange Ratio, at an exercise price per share equal to the strike price per share applicable to such SAR divided by the Equity Award Exchange Ratio. The UnitedHealth Group SARs will continue to be subject to the same terms and conditions as were applicable to the Issuer SARs. |
| Stock Appreciation rightSEC Table II · derivative / convertible security · Conversion / exercise price $8.07 · Expires 2023-05-22 | Direct | 0 |
Reported balance
After 2022-10-03 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2022-10-03 · Disposition to issuer · Disposed 149,685 · Balance 0 F6: These stock appreciation rights ("SARs") are fully vested. Pursuant to the Merger Agreement, the SARs were automatically converted into SARs of UnitedHealth Group, denominated in a number of shares of common stock of UnitedHealth Group equal to the product of the number of shares of Common Stock subject to the Issuer SARs multiplied by the Equity Award Exchange Ratio, at an exercise price per share equal to the strike price per share applicable to such SAR divided by the Equity Award Exchange Ratio. The UnitedHealth Group SARs will continue to be subject to the same terms and conditions as were applicable to the Issuer SARs. |
Filing footnotes · ownership attribution and instrument terms
F1: On October 3, 2022, UnitedHealth Group Incorporated ("UnitedHealth Group") acquired Change Healthcare Inc. (the "Issuer") pursuant to that certain Agreement and Plan of Merger dated as of January 5, 2021 (the "Merger Agreement") by and among the Issuer, UnitedHealth Group and Cambridge Merger Sub Inc., a wholly owned subsidiary of UnitedHealth Group ("Merger Sub"). In accordance with the Merger Agreement, Merger Sub merged with and into the Issuer (the "Merger"), with the Issuer surviving the Merger as a wholly owned subsidiary of UnitedHealth Group. At the effective time of the Merger (the "Effective Time"), each issued and outstanding share of common stock, par value $0.001 per share, of the Issuer (the "Common Stock") (other than certain excluded shares) automatically converted into the right to receive $25.75 per share in cash (the "Merger Consideration"), without interest and less any applicable holding tax.
F2: At the Effective Time of the Merger, all deferred stock units of the Issuer automatically vested and were automatically converted into UnitedHealth Group deferred stock units calculated by taking the merger consideration of $25.75 per share of Common Stock and dividing it by the volume weighted average of the closing sale prices per share of UnitedHealth Group common stock on each of the five full consecutive trading days ending on and including the third business day prior to the Merger closing date (the "Equity Award Exchange Ratio") and continue to be subject to the same terms and conditions (including settlement terms) as were applicable to the Issuer deferred stock units.
F3: At the Effective Time of the Merger, all restricted stock units of the Issuer automatically vested and were automatically converted into United restricted stock units calculated by taking the merger consideration of $25.75 per share of Common Stock of the Issuer and dividing it by the Equity Award Exchange Ratio and continue to be subject to the same terms and conditions (including settlement terms) as were applicable to the Issuer restricted stock units.
F4: These options are fully vested.
F5: In connection with the Merger, stock option awards of the Issuer were automatically converted into an option to purchase a number of shares of common stock of UnitedHealth Group equal to the product of (i) the number of shares of Common Stock subject to the Issuer stock option multiplied by (ii) the Equity Award Exchange Ratio, at an exercise price per share equal to (i) the exercise price of the Issuer stock option divided by (ii) the Equity Award Exchange Ratio. Except as described herein, the UnitedHealth Group options will continue to be subject to the same terms and conditions as were applicable to the existing Issuer stock option.
F6: These stock appreciation rights ("SARs") are fully vested. Pursuant to the Merger Agreement, the SARs were automatically converted into SARs of UnitedHealth Group, denominated in a number of shares of common stock of UnitedHealth Group equal to the product of the number of shares of Common Stock subject to the Issuer SARs multiplied by the Equity Award Exchange Ratio, at an exercise price per share equal to the strike price per share applicable to such SAR divided by the Equity Award Exchange Ratio. The UnitedHealth Group SARs will continue to be subject to the same terms and conditions as were applicable to the Issuer SARs.
Summit Materials, Inc.
Report date February 10, 2025 · Filed February 10, 2025
Section 16 reporting ended · disclosed 2025-02-10. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2025-02-10 transaction · row 1
1 source rowRow 1 · 2025-02-10 · Disposition to issuer · Disposed 62,135 · Balance 0 F1: At or immediately prior to the effective time of the transactions contemplated by the Agreement and Plan of Merger, dated November 24, 2024, by and among Summit Materials, Inc., Quikrete Holdings, Inc., and Soar Subsidiary, Inc., (i) each share of Class A common stock of the issuer held by the reporting person was canceled, retired and converted into the right to receive $52.50 in cash (the "Merger Consideration"), (ii) each restricted stock unit held by the reporting person was fully vested, canceled and converted into the right to receive the Merger Consideration and (iii) each stock option held by the reporting person was fully vested, canceled and converted into the right to receive an amount equal to the excess of the Merger Consideration over the applicable exercise price. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2025-02-10 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2025-02-10 · Disposition to issuer · Disposed 3,341 · Balance 0 F1: At or immediately prior to the effective time of the transactions contemplated by the Agreement and Plan of Merger, dated November 24, 2024, by and among Summit Materials, Inc., Quikrete Holdings, Inc., and Soar Subsidiary, Inc., (i) each share of Class A common stock of the issuer held by the reporting person was canceled, retired and converted into the right to receive $52.50 in cash (the "Merger Consideration"), (ii) each restricted stock unit held by the reporting person was fully vested, canceled and converted into the right to receive the Merger Consideration and (iii) each stock option held by the reporting person was fully vested, canceled and converted into the right to receive an amount equal to the excess of the Merger Consideration over the applicable exercise price. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2025-02-10 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2025-02-10 · Disposition to issuer · Disposed 2,547 · Balance 0 F1: At or immediately prior to the effective time of the transactions contemplated by the Agreement and Plan of Merger, dated November 24, 2024, by and among Summit Materials, Inc., Quikrete Holdings, Inc., and Soar Subsidiary, Inc., (i) each share of Class A common stock of the issuer held by the reporting person was canceled, retired and converted into the right to receive $52.50 in cash (the "Merger Consideration"), (ii) each restricted stock unit held by the reporting person was fully vested, canceled and converted into the right to receive the Merger Consideration and (iii) each stock option held by the reporting person was fully vested, canceled and converted into the right to receive an amount equal to the excess of the Merger Consideration over the applicable exercise price. |
| Options (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $18.00 | Direct | 0 |
Reported balance
After 2025-02-10 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2025-02-10 · Disposition to issuer · Disposed 81,611 · Balance 0 F1: At or immediately prior to the effective time of the transactions contemplated by the Agreement and Plan of Merger, dated November 24, 2024, by and among Summit Materials, Inc., Quikrete Holdings, Inc., and Soar Subsidiary, Inc., (i) each share of Class A common stock of the issuer held by the reporting person was canceled, retired and converted into the right to receive $52.50 in cash (the "Merger Consideration"), (ii) each restricted stock unit held by the reporting person was fully vested, canceled and converted into the right to receive the Merger Consideration and (iii) each stock option held by the reporting person was fully vested, canceled and converted into the right to receive an amount equal to the excess of the Merger Consideration over the applicable exercise price. |
Filing footnotes · ownership attribution and instrument terms
F1: At or immediately prior to the effective time of the transactions contemplated by the Agreement and Plan of Merger, dated November 24, 2024, by and among Summit Materials, Inc., Quikrete Holdings, Inc., and Soar Subsidiary, Inc., (i) each share of Class A common stock of the issuer held by the reporting person was canceled, retired and converted into the right to receive $52.50 in cash (the "Merger Consideration"), (ii) each restricted stock unit held by the reporting person was fully vested, canceled and converted into the right to receive the Merger Consideration and (iii) each stock option held by the reporting person was fully vested, canceled and converted into the right to receive an amount equal to the excess of the Merger Consideration over the applicable exercise price.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 21, 2012 Filed Feb 15, 2013 23:04 UTC | STRYKER CORP SYK · Entity 369 | GrantCommon Stock · Derivative | 4,945 | $53.60 Strike: $53.60 | $265,052.00 |
DisclosureSEC source: 0000310764-13-000040 · edgar.xml · derivative · entry 1 LANCE HOWARD L · CIK 0001220679 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,945 Underlying: Common Stock · 4,945 shares Expires 2022-02-20 F1 · derivative.exercise_date: Stock option granted pursuant to the Stryker Corporation 2006 Long-Term Incentive Plan, exercisable as to 20% on each of the first five anniversaries of the date of grant. Read SEC document |
| February 09, 2011 Filed Feb 11, 2011 22:06 UTC | STRYKER CORP SYK · Entity 369 | GrantCommon Stock · Derivative | 1,578 | $0.00 | $0.00 |
DisclosureSEC source: 0000310764-11-000030 · edgar.xml · derivative · entry 2 LANCE HOWARD L · CIK 0001220679 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,578 Underlying: Common Stock · 1,578 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Stryker Common Stock. F3 · derivative.exercise_date: The restricted stock units vest as to 100% of the shares on March 21, 2012. Vesting will be accelerated in the event of termination of service as a Director of Stryker by reason of disability or death but will otherwise cease upon termination of service as a Director of Stryker. F3 · derivative.expiration_date: The restricted stock units vest as to 100% of the shares on March 21, 2012. Vesting will be accelerated in the event of termination of service as a Director of Stryker by reason of disability or death but will otherwise cease upon termination of service as a Director of Stryker. Read SEC document |
| February 09, 2011 Filed Feb 11, 2011 22:06 UTC | STRYKER CORP SYK · Entity 369 | GrantCommon Stock · Derivative | 4,735 | $0.00 Strike: $59.70 | $0.00 |
DisclosureSEC source: 0000310764-11-000030 · edgar.xml · derivative · entry 1 LANCE HOWARD L · CIK 0001220679 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,735 Underlying: Common Stock · 4,735 shares Expires 2021-02-08 F1 · derivative.exercise_date: Stock option granted pursuant to the Stryker Corporation 2006 Long-Term Incentive Plan, exercisable as to 20% on each of the first five anniversaries of the date of grant. Read SEC document |
| November 10, 2010 Filed Nov 10, 2010 18:14 UTC | STRYKER CORP SYK · Entity 369 | PurchaseCommon Stock | 2,000 | $51.85 | $103,700.00 |
DisclosureSEC source: 0000310764-10-000079 · edgar.xml · nonDerivative · entry 1 LANCE HOWARD L · CIK 0001220679 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,000 Read SEC document |
| February 23, 2010 Filed Feb 24, 2010 20:15 UTC | STRYKER CORP SYK · Entity 369 | GrantCommon Stock · Derivative | 9,995 | $53.09 Strike: $53.09 | $530,634.55 |
DisclosureSEC source: 0000310764-10-000034 · edgar.xml · derivative · entry 1 LANCE HOWARD L · CIK 0001220679 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,995 Underlying: Common Stock · 9,995 shares Expires 2020-02-22 F1 · derivative.exercise_date: Stock option granted pursuant to the Stryker Corporation 2006 Long-Term Incentive Plan, exercisable as to 20% on each of the first five anniversaries of the date of grant. Read SEC document |
| August 10, 2009 Filed Aug 10, 2009 17:58 UTC | STRYKER CORP SYK · Entity 369 | PurchaseCommon Stock | 3,000 | $40.72 | $122,157.60 |
DisclosureSEC source: 0000310764-09-000074 · edgar.xml · nonDerivative · entry 1 LANCE HOWARD L · CIK 0001220679 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,000 F1 · price: Represents the average price for transactions in a range from $40.7192 to $40.72. Read SEC document |
| April 30, 2009 Filed Apr 30, 2009 21:43 UTC | STRYKER CORP SYK · Entity 369 | PurchaseCommon Stock | 3,000 | $38.67 | $116,001.30 |
DisclosureSEC source: 0000310764-09-000047 · edgar.xml · nonDerivative · entry 1 LANCE HOWARD L · CIK 0001220679 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,000 F1 · price: Represents the average price for transactions in a range from $38.66 to $38.67. Read SEC document |
| April 29, 2009 Filed Apr 30, 2009 17:50 UTC | STRYKER CORP SYK · Entity 369 | GrantCommon Stock · Derivative | 13,750 | $37.86 Strike: $37.86 | $520,575.00 |
DisclosureSEC source: 0000310764-09-000045 · edgar.xml · derivative · entry 1 LANCE HOWARD L · CIK 0001220679 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,750 Underlying: Common Stock · 13,750 shares Expires 2019-04-28 F1 · derivative.exercise_date: Stock option granted pursuant to the Stryker Corporation 2006 Long-Term Incentive Plan, exercisable as to 20% on each of the first five anniversaries of the date of grant. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.